Glial and neuroinflammatory targets for treating substance use disorders. (1st November 2017)

• Record Type: Journal Article
• Authors: Bachtell, Ryan K.; Jones, Jermaine D.; Heinzerling, Keith G.; Beardsley, Patrick M.; Comer, Sandra D.
• Is Part Of: Drug and alcohol dependence. Volume 180(2017)
• Page Start: 156
• Page End: 170
• Publication Date: 2017-11-01
• Subjects: Astrocyte -- Microglia -- Innate immune -- Inflammatory -- Cytokine -- Glutamate -- Cocaine -- Opioid -- Morphine -- Psychostimulant -- Alcohol; Drug abuse -- Periodicals; Alcoholism -- Periodicals; 616.86
• DOI: 10.1016/j.drugalcdep.2017.08.003
• Languages: English
• ISSNs: 0376-8716

Abstract

Highlights: Drugs of abuse alter the functioning of astrocytes and microglia. Drug-induced changes in glial function contribute to lasting behavioral changes. Glia-directed pharmacotherapies show promising preclinical and clinical efficacy. Abstract: Background: The plenary session at the 2016 Behavior, Biology and Chemistry: Translational Research in Addiction Conference focused on glia as potential players in the development, persistence and treatment of substance use disorders. Glia partake in various functions that are important for healthy brain activity. Drugs of abuse alter glial cell activity producing several perturbations in brain function that are thought to contribute to behavioral changes associated with substance use disorders. Consequently, drug-induced changes in glia-driven processes in the brain represent potential targets for pharmacotherapeutics treating substance use disorders. Methods: Four speakers presented preclinical and clinical research illustrating the effects that glial modulators have on abuse-related behavioral effects of psychostimulants and opioids. This review highlights some of these findings and expands its focus to include other research focused on drug-induced glia abnormalities and glia-focused treatment approaches in substance use disorders. Results: Preclinical findings show that drugs of abuse induce neuroinflammatory signals and disrupt glutamate homeostasis through their interaction with microglia and astrocytes. Preclinical and clinical studies testing the effects of glial modulators show general effectiveness in reducing behaviors associated with substance use disorders. Conclusions: The contribution of drug-induced glial activity continues to emerge as an intriguing target for substance use disorder treatments. Clinical investigations of glial modulators have yielded promising results on substance use measures and indicate that they are generally safe and well-tolerated. However, results have not been entirely positive and more questions remain for continued exploration in the development and testing of glial-directed treatments for substance use disorders.